The future of vaccination in Latin America: learning from the COVID-19 pandemic.


Journal

Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 17 03 2023
revised: 01 06 2023
accepted: 13 09 2023
medline: 27 11 2023
pubmed: 9 10 2023
entrez: 8 10 2023
Statut: ppublish

Résumé

The SARS-CoV-2 pandemic caused millions of deaths around the world. This dramatic balance requires governments, international organizations, vaccine manufacturers, and the scientific community itself to take stock of what has been done and what could have been done better. In this sense, the tremendous inequity in access to vaccines, the main tool to deal with the pandemic, deserves deep reflection and a set of actions to be carried out by low- and middle-income countries. Among them, the construction of a joint effort to produce their own vaccines and the reconsideration of the bases that govern the intellectual property rights of vaccines and medicines, which harmed equitable access to health, with the consequent loss of many lives that could have been saved.

Identifiants

pubmed: 37806096
pii: S0952-7915(23)00109-7
doi: 10.1016/j.coi.2023.102390
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102390

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Fernando E Díaz (FE)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, C1121ABG CABA, Argentina.

Lourdes Arruvito (L)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, C1121ABG CABA, Argentina.

Jorge Geffner (J)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, C1121ABG CABA, Argentina. Electronic address: jorgegeffner@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH